VivoSeq
Other

Fibromatosis

8

Pipeline Programs↗

0

Active Trials↗

6

Companies Involved↗

Fibromatosis is an early-stage landscape with 8 programs across 6 companies. The most active players are Novartis, SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, Pfizer. 2 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

0/100

Mech. Concentration

20/100

Completion Rate

88/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

Phase 2S

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2Endo Pharmaceuticals logo

Endo Pharmaceuticals

1 program

Phase 3Bayer logo

Bayer

1 program

Phase 3S

SpringWorks Therapeutics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

86%

Small molecule

6 of 7 classified programs — the dominant modality here.

14%ALL OTHERSProtein / enzyme114%

Small molecule leads; the ring shows all 7 classified programs, each share of the total. Modality classified for 100% of 8 pipeline programs.

Analysis

Trial Status

8

clinical trials

Completed7 · 88%
Withdrawn1 · 13%

Clinical Trials

Trial Activity

8 trials

Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar Fibromatosis
Completed·Endo Pharmaceuticals logoEndo Pharmaceuticals·Phase 3·NCT05254457·145 enrolled
Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis
Completed·National Cancer Institute (NCI)·Phase 2·NCT01981551·17 enrolled
Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
Completed·SSpringWorks Therapeutics, Inc.·Phase 3·NCT03785964·142 enrolled
A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)
Completed·YYonsei University·Phase 2·NCT02495519·21 enrolled
Efficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis
Completed·Endo Pharmaceuticals logoEndo Pharmaceuticals·Phase 2·NCT05152173·177 enrolled
Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis
Completed·UUNICANCER·Phase 1/2·NCT00287846·40 enrolled
A Phase 3, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis (PFI) (Also Known as Ledderhose Disease)
Completed·Endo Pharmaceuticals logoEndo Pharmaceuticals·Phase 3·NCT06151197·436 enrolled
Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)
Withdrawn·MMedPacto, Inc.·Phase 2·NCT06219733

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)